유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioedemas, nasljedni - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomid - multipli mijelom - imunosupresivi - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. akord леналидомид u kombinaciji s дексаметазоном indiciran za liječenje multiple myeloma kod odraslih pacijenata koji su primili barem jedan tečaj terapija. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - fulvestrant - otopina za injekciju u napunjenoj štrcaljki - 250 mg - urbroj: jedna napunjena štrcaljka sadrži 250 mg fulvestranta u 5 ml otopine

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - pirfenidon - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 267 mg pirfenidona

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - pirfenidon - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 801 mg pirfenidona

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - ambrisentan - filmom obložena tableta - 5 mg - urbroj: jedna tableta sadrži 5 mg ambrisentana

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - cinakalcet hidroklorid - hiperparatireoidizam - homeostaza kalcija - sekundarni hyperparathyroidismadultstreatment sekundarni hiperparatireoidizam (atg) u odraslih bolesnika s terminala bubrega (esrd) na održavanje диализной terapija. vrtić populationtreatment sekundarni hiperparatireoidizam (atg) u djece u dobi od 3 godina i stariji sa terminala fazi zatajenja bubrega (esrd), koji se nalazi na održavanje диализной terapije, u kojem sekundarni atg nije adekvatno kontroliran pomoću razine terapije (vidi odjeljak 4. Цинакалцет accordpharma može se koristiti kao dio zdravstvenog stanja, uključujući i fosfatnih veziva i/ili vitamina d, steroli, na odgovarajući način (vidi odjeljak 5. karcinom parathyroid žlijezde i primarni hiperparatireoidizam u adultsreduction razvoj гиперкальциемии kod odraslih pacijenata s карциномой parathyroid. primarni atg, za koje паратиреоидэктомия će biti drugačije, na temelju razine kalcija u serumu (kao što je definirano u relevantnim smjernicama za liječenje), ali u kojima паратиреоидэктомия nije klinički ili je kontraindicirano.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.